This article is more than 5 years old. Information may no longer be current.
Selumetinib increased radioiodine uptake in thyroid cancer
Click Here to Manage Email Alerts
The MEK inhibitor selumetinib boosted uptake and retention of radioiodine in patients with refractory thyroid cancer, according to data published in The New England Journal of Medicine.
“In mouse models of thyroid cancer, selective mitogen-activated protein kinase (MAPK) pathway antagonists increase the expression of the sodium–iodide symporter and uptake of iodine,” the researchers wrote. “We conducted a study to determine whether the MAPK kinase (MEK) 1 and MEK2 inhibitor selumetinib could reverse refractoriness to radioiodine in patients with metastatic thyroid cancer.”
Alan L. Ho
After adhering to a low-iodine diet for 5 days followed by a thyrotropin alfa-stimulated iodine-124 (I-124) PET-CT study and then twice-daily treatment with selumetinib 75 mg for 4 weeks, patients underwent a second iodine-24 PET study to determine whether iodine uptake in the lesion or lesions was increased. If a patient experienced increased iodine uptake, the researchers estimated the dose of radioiodine (I-131) required to deliver a projected absorbed dose of at least 2,000 cGy to the lesion and administered radioiodine therapy while also continuing treatment with selumetinib.
Twenty of 24 patients (median age, 61 years) with differentiated thyroid carcinoma of follicular-cell origin or its respective variants were available for evaluation — nine of whom had tumors with BRAF mutations and five of whom had tumors with NRAS mutations. The researchers found increased I-124 uptake in 12 patients — four with BRAF mutations and five with NRAS mutations. Eight of these 12 met the threshold for treatment with I-131, according to the researchers, including all five with NRAS mutations. Five of these eight patients had partial responses and three had stable disease, and all patients experienced a mean reduction of 89% in serum thyroglobulin levels. The researchers determined that selumetinib was not responsible for any toxic effects of grade 3 or higher. One patient, however, was diagnosed with myelodysplastic syndrome, with eventual progression to leukemia, more than 51 weeks after treatment with I-131.
“These results provide a proof of principle that MEK inhibitors can induce iodine uptake and retention in thyroid tumors,” the researchers wrote. “An advantage of this therapeutic strategy over long-term treatment with small-molecule kinase inhibitors alone is that only a short course of drug therapy is required to elicit a durable clinical effect.”
Disclosure: This study was supported by grants from the American Thyroid Association, the Society of Memorial Sloan-Kettering Cancer Center, the NIH, AstraZeneca and Genzyme. The I-124 PET studies were supported in part by a grant from the In-Vivo Cellular and Molecular Imaging Center.
Perspective
Back to Top
Bryan Haugen, MD
Of the approximately 2,000 deaths from thyroid cancer each year in the US, a majority are patients with differentiated thyroid cancer that is progressive and unresponsive to radioiodine therapy. Targeted agents to ‘redifferentiate’ these thyroid cancers to concentrate sufficient radioiodine for meaningful therapy would be a major advance in our field. The MAPK pathway is a major driver in many of these cancers and the group from Memorial Sloan-Kettering Cancer Center has previously shown that a specific inhibitor of MEK in this pathway increased radioiodine uptake in a transgenic mouse model of advanced thyroid cancer. In the current study, Ho et al use a carefully designed clinical trial to show that 4 weeks of selumetinib (MEK inhibitor) therapy increased radioiodine uptake in 12 of 20 evaluable patients and to a sufficient amount in eight of 20 patients to warrant radioiodine therapy. They further showed that many of these patients have had a clinically meaningful early response and that this response may be correlated with mutation status of the tumor. If these data can be confirmed and extended to long-term clinical outcome benefit in a larger multicenter study, this would be a tremendous advance in our field and benefit for our patients with radioiodine-resistant thyroid cancer.
Perspective
Back to TopSteven I. Sherman, MD
The study by Ho and colleagues introduces a novel approach to trying to augment the effectiveness of radioiodine therapy for differentiated thyroid cancer. If validated in larger, multicenter cohorts, this therapeutic strategy could expand the use of radioiodine to treat metastatic disease as well as potentially provide a way to enhance the effectiveness of adjuvant radioiodine therapy in the absence of known metastatic disease. Caution would need to be applied, however, to ensure that this does not encourage more widespread use of radioiodine when it is truly ineffective or unnecessary, as significant long-term toxicities remain of major concern.
Click Here to Manage Email Alerts